The stock of Zogenix, Inc. (NASDAQ:ZGNX) is a huge mover today! About 77,357 shares traded hands. Zogenix, Inc. (NASDAQ:ZGNX) has risen 6.61% since March 8, 2016 and is uptrending. It has underperformed by 2.70% the S&P500.
The move comes after 6 months negative chart setup for the $256.26 million company. It was reported on Oct, 11 by Barchart.com. We have $8.80 PT which if reached, will make NASDAQ:ZGNX worth $28.19 million less.
Analysts await Zogenix, Inc. (NASDAQ:ZGNX) to report earnings on November, 14. They expect $-0.95 EPS, down 43.94% or $0.29 from last year’s $-0.66 per share. After $-0.78 actual EPS reported by Zogenix, Inc. for the previous quarter, Wall Street now forecasts 21.79% negative EPS growth.
Zogenix, Inc. (NASDAQ:ZGNX) Ratings Coverage
Out of 2 analysts covering Zogenix (NASDAQ:ZGNX), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Zogenix has been the topic of 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The firm earned “Buy” rating on Friday, August 14 by Brean Capital. On Saturday, August 15 the stock rating was upgraded by Zacks to “Hold”. On Tuesday, August 11 the stock rating was maintained by Leerink Swann with “Outperform”. As per Thursday, September 17, the company rating was maintained by Brean Capital. The firm has “Sell” rating by Zacks given on Thursday, August 6.
According to Zacks Investment Research, “Zogenix, Inc. is a pharmaceutical company engaged in the development and commercialization of treatment products for central nervous system disorders and pain. Its first commercial product, SumavelÂ™ DoseProÂ™ is a needle-free Delivery System used in the treatment of acute migraine and cluster headache in a pre-filled, single-use delivery system. Its lead product candidate, ZX002, is a novel, oral and single-entity controlled-release formulation of hydrocodone used for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix, Inc. is headquartered in San Diego, CA.”
More notable recent Zogenix, Inc. (NASDAQ:ZGNX) news were published by: Fool.com which released: “Zogenix, Inc Gained 29% in 2015 — Here’s Why” on January 14, 2016, also Fool.com with their article: “Zogenix, Inc. Shares Galloped 15% Higher in February — Here’s Why” published on March 10, 2016, Fool.com published: “Why Zogenix, Inc. Shares Were Throttled” on April 27, 2015. More interesting news about Zogenix, Inc. (NASDAQ:ZGNX) were released by: Fool.com and their article: “Why Zogenix, Inc. Shares Rocketed 22% Higher in May” published on June 05, 2015 as well as Fool.com‘s news article titled: “Zogenix Inc. Shares Crumbled in March — Here’s Why” with publication date: April 10, 2015.
ZGNX Company Profile
Zogenix, Inc., incorporated on May 11, 2006, is a pharmaceutical firm engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia. The Company’s lead product candidate, ZX008, is a low-dose fenfluramine. The Firm is also engaged in the development of Relday. It is also engaged in manufacturing Sumavel DosePro (sumatriptan injection), a needle-free delivery system, under an Asset Purchase Agreement with Endo Ventures Bermuda Limited and Endo Ventures Limited (collectively, Endo). The Firm sells Sumavel DosePro to Endo.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.